Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SH T00268C · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Arm 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| SH T00268C | DRUG | 1250 mg experimental drug od |
| PTK787/ ZK 222584 | DRUG | 1250 mg experimental drug bid (500mg + 750mg) |
Inclusion Criteria: * Non small cell lung cancer, Stage IIIB or Stage IV * One and only 1 prior platinum-based chemotherapy * No other uncontrolled concurrent illness * Use of highly effective birth control methods in males or females with reproductive potential Exclusion Criteria: * Previous par...
Top 20 of 90 competitors
SH T00268C is an investigational small molecule being studied for the treatment of Non Small Cell Lung Cancer. It is currently in Phase 2 clinical development and is not approved by the FDA. The drug is being evaluated for its safety and efficacy in patients with this condition.
SH T00268C is being developed by Bayer AG, a multinational pharmaceutical company. Bayer AG is publicly traded under the ticker symbol BAYRY. The company is conducting clinical trials to evaluate the drug's potential in treating Non Small Cell Lung Cancer.
SH T00268C is in Phase 2 clinical development. It is an investigational drug, meaning it has not yet received regulatory approval. The drug is being studied for its safety and efficacy in patients with Non Small Cell Lung Cancer, with one completed Phase 2 trial.
SH T00268C has one completed clinical trial, identified as NCT00160043. This Phase 2 study evaluated the safety and efficacy of the drug in treating Non Small Cell Lung Cancer. The trial enrolled 112 participants and was conducted in France and Germany.
SH T00268C is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for Non Small Cell Lung Cancer. The drug has completed one clinical trial, but it has not yet received regulatory approval from the FDA or any other regulatory authority.